Review article: Interferon and hepatitis C factors predicting therapeutic outcome

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 6, 1998, Pages 509-518

  Mabee, C L ^a   Crippin, J S ^b   Lee, W M ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; HEPATITIS C; HUMAN; IMMUNOSTIMULATION; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031863782     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00328.x     Document Type: Review

References (110)

1. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.
2. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
3. NIH Consensus Development Conference. Management of Hepatitis C. Hepatology 1997; 26S: 1-155.
4. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56.
5. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9: 235-9.
6. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996; 23: 909-16.
7. Pignatelli M, Waters J, Brown D, et al. HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B infection. Hepatology 1986; 6: 349-53.
8. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991; 183: 1-11.
9. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
10. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994; 39: 241-75.
11. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315: 1575-8.
12. Thomson BJ, Lever AML, Doran M, Webster ADB. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1987; 1: 539-41.
13. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.
14. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized. double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
15. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
16. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
17. Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25: 211-15.
18. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastoenterology 1997; 112: 463-72.
19. Sheeham MM, Doyle CT, Whelton M, Kenny-Walsh E. Hepatitis C virus liver disease in women infected with contaminated anti-D immunoglobulin. Histopathology 1997; 30: 512-17.
20. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992; 27: 1906-11.
21. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301.
22. Camps J, Crisostomo S, Garcia-Granero M, et al. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-17.
23. Yoshioka K, Higashi Y, Yamada M, et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 1995; 15: 57-62.
24. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
25. Rossini A, Ravaggi A, Biasi L, et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997; 26: 1012-17.
26. Mazzella G, Salzetta A, Casanova S, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sci 1994; 39: 866-70.
27. Coverdale S, Byth K, Field J, Liddle C, Lin R, Farrell GC. Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology 1995; 22: 1065-71.
28. Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med 1969; 281: 1081-6.
29. Soardo G, Pirisi M, Fonda M, et al. Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J Interferon Cyto Res 1995; 15: 705-12.
30. Pagliaro L, Crixi A, Camma C, et al. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-8.
31. Camps J, Garcial-Granero M, Riezu-Boj JI, et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994; 21: 4-11.
32. Magrin S, Crixi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-α (or corticosteroid treatment. Hepatology 1994; 19: 273-9.
33. Serfaty L, Giral P, Loria A, et al. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
34. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3.
35. Banner BF, Barton AL, Cable EE, et al. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 1995; 8: 232-8.
36. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
37. Davis GL, Lindsay K, Albrecht J, et al. Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis. The Hepatitis Interventional Therapy Group. J Viral Hepat 1994; 1: 55-63.
38. Van Thiel DH, Friedlander L, Fagiuoli S, et al. Response to interferon-α therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-15.
39. Olynyk JK, Reddy KR, Di Bisceglie AM,et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-9.
40. Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-8.
41. Piperno A, Sampietro M, D'Alba R, et al. Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16: 248-54.
42. Tanaka M, Sato S, Fujiyama S, et al. Clinical study of IgA antibody against hepatitis C virus core antigen in patients with type C chronic liver disease. Dig Dis Sci 1995; 40: 457-64.
43. Taura Y, Fujiyama S, Kawano S, et al. Clinical evaluation of titration of hepatitis C virus core antibody and its subclasses. J Gastroenterol Hepatol 1995; 10: 270-6.
44. Sato A, Nakamura H, Sho Y, et al. Quantitation of anti-hepatitis C virus antibodies in interferon-treated patients by S29-1/S4 ELISA. J Med Virol 1995; 47: 226-30.
45. Quiroga JA, Bosch O, Gonzalez R, et al. Immunoglobulin M antibody to hepatitis C virus during interferon therapy for chronic hepatitis C. Gastroenterology 1992; 103: 1285-9.
46. Quiroga JA, van Binsbergen J, Wang CY, et al. Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome. Hepatology 1995; 22: 1635-40.
47. Nagayama R, Miyake K, Tsuda F, et al. IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of liver disease in patients with acute or chronic hepatitis C. J Med Virol 1994; 42: 311-17.
48. Sakashita H. Clinical significance of antibody to Y19 protein in non-A, non-B chronic liver disease. Fukuoka Igaku Zasshi 1993; 84: 159-72.
49. Tanaka E, Kiyosawa K, Matsumoto A, et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1996; 23: 1330-3.
50. Greenway AL, Hertzig PJ, Devenish RJ, et al. Immunolocalisation of interferon-alpha in hepatitis C patients and its correlation with response to interferon-alpha therapy. J Hepatol 1994; 21: 842-52.
51. Franco A, Barnaba V, Natali P, et al. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988; 8: 449-54.
52. Pignatelli M, Waters J, Brown D, et al. HLA class I antigens on hepatocyte membrane during recovery from acute hepatitis B infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology 1986; 6: 349-53.
53. Ballardini G, Groff P, Giostra F, et al. Hepatocellular expression of HLA-A, B, C molecules predicts primary response to interferon in patients with chronic hepatitis C. Am J Clin Pathol 1994; 102: 746-51.
54. Morishima I, Kumada T, Nakano S, et al. Serum levels of soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alpha. Scand J Gastroenterol 1995; 30: 807-11.
55. Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158: 1473-81.
56. Koziel MJ, Walker BD. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol 1997; 19: 69-83.
57. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99: 1472-7.
58. Russo-Mancuso G, Di Gregorio F, Passero E, et al. Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to α-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study. Br J Haematol 1995; 89: 291-8.
59. Guadagnino V, Caroleo B, Izzi A, et al. T-lymphocyte subpopulations as factors predicting clinical response to interferon in hepatitis C virus-related chronic active hepatitis. Infection 1995; 23: 189-90.
60. Nathan CF, Murray HW, Weibe ME, et al. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-89.
61. Spits H, Yssel H, Paliard X, et al. IL-4 inhibits IL-2 mediated induction of human lymphokine-activated killer cells, but not generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 1988; 141: 29-36.
62. Aoki T, Kikuchi H, Miyatake SI, et al. Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity. J Exp Med 1989; 170: 583-8.
63. Kern DE, Gillis S, Okada M, et al. The role of interleukin 2 (IL-2) in the differentiation of cytotoxic T cells: the effect of monoclonal anti-IL2 antibody and adsorption with IL-2 dependent T cell lines. J Immunol 1981; 127: 1323-8.
64. Cacciarelli TV, Martinez OM, Gish RG, et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa. Hepatology 1996; 24: 6-9.
65. Lee CA, Kernoff PB, Karayiannis R, Thomas HC. Interferon therapy for chronic non-A, non-B and chronic delta liver disease in haemophilia. Br J Haematol 1989; 72: 235-8.
66. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996; 23: 1117-25.
67. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comite des Anti-Viraux. J Infect Dis 1992; 165: 723-6.
68. Mauss S, Heintges T, Adams O, et al. Treatment of chronic hepatitis C with interferon-alpha in patients infected with the human immunodeficiency virus. Hepatogastroenterology 1995; 42: 528-34.
69. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585-91.
70. Marcellin P, Boyer N, Benhamou JP. Interferon-alpha therapy for chronic hepatitis C in special patient populations. Dig Dis Sci 1996; 41: S126-30.
71. Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29: 1039-43.
72. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-9.
73. Ono K, Sata M, Murashima S, et al. Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res 1996; 20: 1560-3.
74. Mochida S, Ohnishi K, Matsuo S, et al. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996; 20: A371-7(Absrract).
75. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20: 1115-20.
76. Lau JYN, Davis GL, Kniffen J, et al. Significance of hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
77. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-83.
78. Yamada G, Takahashi M, Miyamoto R, et al. Prediction of interferon effect in chronic hepatitis C by both quantification and genotyping of HCV-RNA. Dig Dis Sci 1994; 39: 441.
79. Mita E, Hayashi N, Hagiwara H, et al. Predicting interferon therapy efficacy from hepatitic C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977-82.
80. Saracco G, Rizzetto M. Predictors of response to interferon therapy. Dig Dis Sci 1996; 41: S115-20.
81. Booth JCL, Foster GR, Kumar U, et al. Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon α. Gut 1995; 36: 427-32.
82. Orito E, Mizokami M, Suzuki K, et al. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995; 46: 109-15.
83. Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 1996; 124: 1058-60.
84. Qian C, Camps J, Maluenda MD, et al. Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy. J Hepatol 1992; 16: 380-3.
85. Willems M, Peerlinck K, Moshage H, et al. Hepatitis C virus-RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells. J Med Virol 1994; 42: 272-8.
86. Hamid S, Stell M, Casey DL, et al. Measurement of hepatitis C virus RNA in peripheral blood mononuclear cells (PBMC) does not predict treatment responses in chronic hepatitis C. Gastroenterology 1997; 112: A1277(Abstract).
87. Shindo M, Arai K, Sokawa Y, et al. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α-therapy. Ann Intern Med 1995; 122: 586-91.
88. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
89. Ohno T, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201-7.
90. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
91. Chemello L, Alberti A, Rose K, et al. Hepatitis C serotype and response to interferon therapy. N Engl I Med 1992; 330: 143.
92. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
93. Tsubota A, Chayama K, Ikeda K, et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 1993; 8: 535-9.
94. 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 1273-80.
95. Hino K, Sainokami S, Shimoda K, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299-305.
96. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
97. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996; 125: 634-9.
98. De Salvo GL, Noventa F, Chemello L, et al. Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models. J Viral Hepatol 1997; 4: 19-83.
99. Pol S, Thiers V, Nousbaum JB, et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995; 108: 581-3.
100. Enomoto N, Sakamoto N, Kurosaki M, et al. The hypervariable region of HCV genome changes sequentially the progression of acute HCV infection to chronic hepatitis. J Hepatol 1993; 17: 415-16.
101. Kurosaki M, Enomoto N, Marumo F, et al. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 1993; 18: 1293-9.
102. Okada SI, Akahane Y, Suzuki H, et al. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619-24.
103. Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994; 20: 1121-30.
104. Koizumi K, Enomoto N, Kurosaki M, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22: 30-5.
105. Enomoto N, Sato C, Kurosaki M, et al. Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene. J Hepatol 1994; 20: 252-61.
106. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5a gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
107. Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-β therapy. Hepatology 1997; 25: 750-3.
108. Germanidis G, Pellerin M, Bastie A, et al. Study of the genetic heterogeneity of the NS5A region of the HCV-1b genome and evolution under interferon alfa therapy. Hepatology 1996; 24: A551(Abstract).
109. Nelson DR, Gray AH, Kolberg JA, et al. Variations of hepatitis C virus NS5B sequence (nucleotides 8261-8566) do not correlate with response to interferon-alpha therapy. J Viral Hepatol 1995; 2: 285-92.
110. Colloredo G, Bellati G, Ricci A, et al. HCV-RNA as a predictor of relapse after interferon therapy for chronic hepatitis C. Hepatology 1996; 24S: A156(Abstract).